Pfizer announced on April 14 that it has decided to discontinue development of Danuglipron, an oral glucagon-like peptide-1 agonist drug for weight control.

Zhitongcaijing · 04/14 11:09
Pfizer announced on April 14 that it has decided to discontinue development of Danuglipron, an oral glucagon-like peptide-1 agonist drug for weight control.